The kinetic and biological activity of different loaded rhBMP-2 calcium phosphate cement implants in rats.
The healing of large bone defects can be improved by osteogenic bone graft substitutes, due to growth factor inclusion. A sustained release of these growth factors provides more efficient bioactivity when compared with burst release and might reduce the dose required for bone regeneration, which is desirable for socioeconomical and safety reasons. In this study, we compared different rhBMP-2 loadings in a sustained release system of CaP cement and PLGA-microparticles and were able to couple kinetic to biological activity data. Fifty-two rats received a critical-size cranial defect, which was left open or filled with the cement composites. The implants consisted of plain, high, and five-fold lower dose rhBMP-2 groups. Implantation time was 4 and 12 weeks. Longitudinal in vivo release was monitored by scintigraphic imaging of (131)I-labeled rhBMP-2. Quantitative analysis of the scintigraphic images revealed a sustained release of (131)I-rhBMP-2 for both doses, with different release profiles between the two loadings. However, around 70% of the initial dose was retained in both implant formulations. Although low amounts of rhBMP-2 were released (2.4 +/- 0.8 mug in 5 weeks), histology showed defect bridging in the high-dose implants. Release out of the low-dose implants was not sufficient to enhance bone formation. Implant degradation was limited in all formulations, but was mainly seen in the high-dose group. Low amounts of sustained released rhBMP-2 were sufficient to bridge critically sized defects. A substantial amount of rhBMP-2 was retained in the implants because of the slow release rate and the limited degradation.
Bodde
Esther W H
EW
Department of Periodontology and Biomaterials, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Boerman
Otto C
OC
Russel
Frans G M
FG
Mikos
Antonios G
AG
Spauwen
Paul H M
PH
Jansen
John A
JA
D000818:Animals; D001672:Biocompatible Materials / Q000493:pharmacokinetics*; D001843:Bone Cements / Q000493:pharmacokinetics*; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001861:Bone Regeneration / Q000187:drug effects; D002130:Calcium Phosphates / Q000493:pharmacokinetics*; D004337:Drug Carriers / Q000378:metabolism; D020007:Implants, Experimental; D007457:Iodine Radioisotopes / Q000032:analysis; D019344:Lactic Acid / Q000493:pharmacokinetics*; D008297:Male; D008863:Microspheres; D011100:Polyglycolic Acid / Q000493:pharmacokinetics*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011877:Radionuclide Imaging; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics; D012886:Skull / Q000293:injuries; D055114:X-Ray Microtomography
C525718:BMP2 protein, human; D001672:Biocompatible Materials; D001843:Bone Cements; D055396:Bone Morphogenetic Protein 2; D002130:Calcium Phosphates; D004337:Drug Carriers; D007457:Iodine Radioisotopes; D011994:Recombinant Proteins; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C020243:calcium phosphate